Company XTL Biopharmaceuticals Ltd. Nasdaq

Equities

XTLB

US98386D3070

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-07-12 pm EDT			5-day change	1st Jan Change
2.48 ^USD	-7.29%		+7.83%	+145.53%

Jun. 05	XTL Biopharmaceuticals Signs Deal to Acquire The Social Proxy	MT
Jun. 05	XTL Biopharmaceuticals Ltd. announced that it has received $1.5 million in funding	CI

XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Number of employees: 5

Managers	Title	Age	Since
Shlomo Shalev CEO	Chief Executive Officer	62	14-12-29
Itay Weinstein DFI	Director of Finance/CFO	52	98-12-31
Doron Turgeman CHM	Chairman	56	14-12-29
Daphna Paran CTO	Chief Tech/Sci/R&D Officer	-	16-03-03

Members of the board	Title	Age	Since
Shlomo Shalev CEO	Chief Executive Officer	62	14-12-29
Iris Shapira Yalon BRD	Director/Board Member	57	20-01-28
Alexander Rabinovitch BRD	Director/Board Member	53	17-03-31
Doron Turgeman CHM	Chairman	56	14-12-29
Dobroslav Melamed BRD	Director/Board Member	46	14-12-07
Osnat Hillel Fain BRD	Director/Board Member	57	15-02-28
Jonathan Schapiro BRD	Director/Board Member	63	14-12-07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	514,205,799	479,737,353 ( 93.30 %)	0	93.30 %

Name	Equities	%	Valuation
Alexander Rabinovitch 23.54 %	128,288,887	23.54 %	3 M $
Shlomo Shalev 0.5541 %	3,019,309	0.5541 %	64 251 $
Ayalon Provident Funds Management Co. 0.1039 %	566,000	0.1039 %	12 044 $
Doron Turgeman 0.0624 %	340,000	0.0624 %	7 235 $
Ayalon Mutual Funds Ltd. 0.0551 %	300,000	0.0551 %	6 384 $
Iris Shapira Yalon 0.000000 %	0	0.000000 %	- $
Dobroslav Melamed 0.000000 %	0	0.000000 %	- $
Osnat Hillel Fain 0.000000 %	0	0.000000 %	- $
Jonathan Schapiro 0.000000 %	0	0.000000 %	- $

Name	Equities	%	Valuation
Noked Israel Ltd. 3.650 %	198,888	3.650 %	483 298 $
Morgan Stanley Capital Services LLC 0.7189 %	39,171	0.7189 %	95 186 $
Citadel Securities GP LLC 0.2502 %	13,631	0.2502 %	33 123 $
UBS Securities LLC 0.1276 %	6,954	0.1276 %	16 898 $
Ayalon Provident Funds Management Co. 0.1101 %	6,000	0.1101 %	14 580 $
BNP Paribas Arbitrage SA 0.005506 %	300	0.005506 %	729 $

XTL Biopharmaceuticals Ltd.

26 Ben-Gurion Street

5112001, Ramat Gan

+972 3 611 6600

http://www.xtlbio.com

address XTL Biopharmaceuticals Ltd.(XTLB)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.10%	47.07B
LONZA GROUP AG	+46.45%	42.06B
IQVIA HOLDINGS INC.	-3.12%	39.98B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	33.02B
CELLTRION, INC.	-6.30%	27.9B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.63B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.37B
MEDPACE HOLDINGS, INC.	+44.52%	13.45B
BIO-TECHNE CORPORATION	+0.19%	12.03B

Other Biotechnology & Medical Research